32 results about "Bone metabolism disorder" patented technology

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin alphaVbeta3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin alphaVbeta3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin alphaVbeta3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin αVβ3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin αVβ3, which formulations are substantially free of surfactant, inorganic salts, and / or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and / or activity of integrin αVβ3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.

An object of the present invention is to provide a hollow fiber membrane with enhanced phosphorus-removing performance without impairing antithrombogenicity in order to inhibit in vivo accumulation of phosphate ions in living body that might cause bone metabolism disorders. The present inventors have found that a hollow fiber membrane having a specific membrane structure and a specific membrane composition possesses a very useful range for inner surface charges of the membrane. More particularly, the inventors have discovered that the above object can be achieved in a limited range in which the zeta potential on the inner surface of a hollow fiber membrane measured under given certain conditions is greater than −3.0 mV but less than 0 mV. This finding has led to the completion of the present invention.

The invention relates to the novel discovery that inhibiting a C / CLP modulates (e.g., inhibits) inflammation, as well as, bone and tissue destruction in arthritis. The present invention relates to compositions and methods for the treatment of bone metabolism and connective tissue disorders and diseases (e.g., bone metabolism disorders, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, and osteoporosis) by modulating (e.g., inhibiting) at least one C / CLP. In particular where the inhibition of at least one C / CLP results in the inhibition of osteoclast activity, including but not limited to, osteoclast maturation, osteoclast differentiation, osteoclast proliferation, and osteoclastogenesis. One particular embodiment of the invention relates to inhibiting the expression or activity of one or more C / CLPs.

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.

The invention relates to a phosphorus-containing compound and application thereof. Compared with the bisphosphonate in the existing structure, the compound provided by the invention has higher lipotropism, and can reduce drug metabolism and improve effective bioavailability. When applied to the treatment of abnormal bone metabolism, the compound provided by the invention can reduce the dosage and the side effect. The phosphorus-containing compound provided by the invention has, but is not limited to, the following drug actions: improving the bone mineral density of patients with osteoporosis, reducing the fracture risk, easing the bone metastatic cancer pain, and treating bone metastasis, hypercalcemia and other diseases.

The invention relates to the technical field of cod liver oil, in particular to a blending method of cod liver oil preventing the osteoporosis. The blending method comprises the following steps: extracting the cod liver oil from nontoxic ocean cod liver, then determining the content of vitamin D and vitamin A, then blending into a high-concentration cod liver oil raw material, a ratio of VD3 unitsto retinol units in the high-concentration cod liver oil is 2:1; and adding antioxidant (vitamin E and the like) of a given ratio, and then blending with the fish oil or vegetable oil to form cod liver oil drops. The technical scheme of the invention aims at preventing the osteoporosis, and mainly targets at the users such as primary osteoporosis patients and critical people such as the elderly and post-menopause women, and can be used for a long time; and 2, the vitamin A units in the invention are about half of the vitamin D units, after the natural cod liver oil is used by the osteoporosispatients for a long time, and the bone metabolism abnormality caused by the deficiency of the vitamin A can be prevented.

A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of Solatium glaucophyllum comprising from about 0.8 to about 2.2 weight % of a mixture of 1,25-dihydroxyvitamin D3 glycosides and quercetin glycosides present in a ratio of about 1:100 to 1:200 parts by weight. There are also provided food or dietary composition and food supplement designed for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans which comprises an efficient amount of the said plant extract of Solanum glaucophyllum and a source of calcium.

Provided is a pharmaceutical composition for the treatment and / or prophylaxis of abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.

The object of the present invention is to provide a therapeutic agent or a prophylactic agent for a disease resulting from an abnormal bone metabolism, especially osteoporosis which is more effective than conventional agents. Excellent therapeutic effect or prophylactic effect on a disease resulting from an abnormal bone metabolism, especially osteoporosis, compared with the effect in administration of each compound alone can be obtained by the combination of an N-hydroxybenzamidine derivative represented by Formula (I) or a salt thereof with an activated vitamin D or a prodrug thereof.

Novel bisphosphonate cyclic acetal compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating bone metabolism disorders, such as abnormal calcium and phosphate metabolism.

The invention discloses a medicine for treating uremic malnutrition and a preparation method thereof. The medicine is mainly prepared from humifuse euphorbia herb, radix astragali, codonopsis pilosula, poria cocos, rhizoma atractylodis macrocephalae, rhizoma polygonati, herba cistanche and medicinal fermented mass. The medicine has the effects of replenishing qi to invigorate the spleen, tonifying deficiency and harmonizing the stomach, resolving dampness and removing stasis, is suitable for diseases such as uremic malnutrition, mineral and bone metabolism disorder, interior accumulation of dampness and turbid, and spleen-kidney qi deficiency, has a remarkable curative effect, and is safe and free from side effects.

The present invention provides compositions and methods for providing controllable local delivery of a conjugate of chloroquine (CQ) and a bisphosphonate to treat diseases characterized by abnormal bone metabolism. In certain embodiments, the invention is used as a treatment for a subject with diseases and disorders characterized by bone loss.

The invention relates to phosphorus-containing compound and its medicament application for treatment of bone metabolism abnormity. Compared with bisphosphonates of existing structures, the compound in the invention can decrease oxidative metabolism, and increase the effective bioavailability. In addition, applying the compound for treatment of bone metabolism abnormity, can reduce the dosage and side effects. The phosphorus-containing compound in the invention is especially suitable for the treatment of hypercalcemia diseases.

A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing / treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing / treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc. can also be used as test agents for gastric secretory function. Furthermore, the polypeptide or receptor of the present invention and the DNA of the present invention are also useful for screening the agents for the prevention / treatment described above.

The invention provides a construction method for an RANKL recombinant protein expression vector, which is characterized by comprising the following steps of: (1) obtaining a full length of a mouse RANKL gene by using an in-vitro molecular cloning technology; (2) determining that the obtained clone sequence is completely consistent with the sequence in the database through sequencing; furthermore,recombining the mouse RANKL gene into a pET-32a expression vector through a gene recombination technology, and successfully constructing the RANKL recombinant protein expression vector. The inventionalso provides an application of the RANKL recombinant protein expression vector in preparation of drugs for treating diseases related to abnormal bone metabolism; wherein the bone metabolism abnormality related diseases comprise osteosclerosis and periapical caries and odontocele. According to the RANKL recombinant protein expression vector disclosed by the invention, a large amount of RANKL recombinant proteins can be induced and expressed in vitro, and finally, the differentiation and bone absorption functions of osteoclasts are promoted through the RANKL recombinant proteins, so that osteosclerosis and periodontal cardiopathy are treated and improved.

An object of the present invention is to provide a preventive drug and a therapeutic drug for diseases caused by abnormal bone metabolism, especially osteoporosis, which is more effective than conventional drugs. Combined use of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine, or a salt thereof; and at least one compound selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof can exert higher bone resorption inhibitory effect and provide a preventive effect and a therapeutic effect for diseases caused by abnormal bone metabolism, especially osteoporosis as compared with administration of the respective agents respectively.

The invention belongs to the technical field of hemodialysis concentrates, and particularly relates to a concentrate obtained by supplementing palmatol active vitamin D (C27H44O3) into a citric acid hemodialysis concentrate. The content of the paracetamol active vitamin D is 0.15 to 0.30 g / 5L. The concentrate provided by the invention can be slowly perfused in a hemodialysis manner, the content ofvitamin D in the blood of a nephrotic patient is controlled within a reasonable concentration range of a human body, loss of vitamin D in the blood is prevented, vitamin D lacked by the nephrotic patient is supplemented, minerals, bone metabolism disorder and complications of the mineral substances and the bone metabolism disorder of the chronic nephrotic patient are effectively treated, and thena higher survival rate is brought to the nephrotic patient. Meanwhile, compared with oral vitamin D capsules and intravenous injection of vitamin D, the vitamin D is added into the citric acid hemodialysis concentrate and hemodialysis is carried out, so that the preparation method is an optimal way for treating mineral substances, bone metabolic disorders and complications thereof of patients with chronic kidney diseases at present.

The invention discloses asiaticoside, and a function of a pharmaceutically acceptable derivative thereof in bone metabolic abnormality. The asiaticoside has an adjustment function on simultaneously inhibiting osteoclast formation under the situation of bone metabolic abnormality, is low in effective dosage, and has a better effect on adjusting bone metabolic abnormality. The invention defines an intervention way of an asiaticoside related drug. The invention clarifies that a molecular mechanism in a bone microenvironment and a potential pharmacology intervention way are crucial to identifyinga novel treatment compound.

It is intended to provide a preventive agent or a therapeutic agent for a disease caused by abnormal bone metabolism, particularly for osteoporosis, which is more effective than ever before. By combined application of N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]pentoxy}-benzamidine or a salt thereof and one or more compounds selected from the group consisting of etidronic acid, clodronic acid, pamidronic acid, tiludronic acid, risedronic acid, minodronic acid, ibandronic acid, zoledronic acid, and salts thereof, a higher bone resorption inhibitory action compared with the administration of a single compound is exhibited, and an excellent preventive effect and therapeutic effect for a disease caused by abnormal bone metabolism, particularly for osteoporosis can be obtained.

An object of the present invention is to provide a hollow fiber membrane with enhanced phosphorus-removing performance without impairing antithrombogenicity in order to inhibit in vivo accumulation of phosphate ions in living body that might cause bone metabolism disorders.The present inventors have found that a hollow fiber membrane having a specific membrane structure and a specific membrane composition possesses a very useful range for inner surface charges of the membrane. More particularly, the inventors have discovered that the above object can be achieved in a limited range in which the zeta potential on the inner surface of a hollow fiber membrane measured under given certain conditions is greater than −3.0 mV but less than 0 mV. This finding has led to the completion of the present invention.

The invention discloses a method for obtaining RANKL recombinant protein with biological activity. The method is characterized by comprising the following steps: (1) expressing the RANKL recombinant protein in a large quantity through induction in vitro; (2) obtaining RANKL recombinant protein with biological activity by purification; and (3) identifying the biological activity of the RANKL recombinant protein through promotion of differentiation of osteoclast of the RANKL recombinant protein in vitro. The invention further discloses application of the RANKL recombinant protein with biologicalactivity in preparation of a drug for treating bone metabolic disorder diseases. The application is characterized in that the RANKL recombinant protein with biological activity is obtained by in-vitro induction expression, purification and identification of the RANKL recombinant protein. A large quantity of the RANKL recombinant protein with biological activity can be obtained through in-vitro induction expression and purification of the RANKL recombinant protein, and has potentials to become a new way for treating and improving bone sclerosis and periapical granuloma.

A method is provided for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans. It comprises providing to a subject in need of that a calcium containing or calcium enriched diet combined with the administration of an efficient amount of a plant extract of Solatium glaucophyllum comprising from about 0.8 to about 2.2 weight % of a mixture of 1,25-dihydroxyvitamin D3 glycosides and quercetin glycosides present in a ratio of about 1 : 100 to 1 :200 parts by weight. There are also provided food or dietary composition and food supplement designed for preventing or treating bone or musculoskeletal metabolism disorders or kidney malfunction in humans which comprises an efficient amount of the said plant extract of Solanum glaucophyllum and a source of calcium.

Disclosed is a therapeutic or prophylactic agent for diseases associated with abnormal bone metabolism, particularly osteoporosis, which is more effective than conventional therapeutic or prophylactic agents. Specifically disclosed is a combination of an N-hydroxybenzamidine derivative represented by formula (I) or a salt thereof and active vitamin D or a prodrug thereof, which has a superior therapeutic or prophylactic effect on diseases associated with abnormal bone metabolism, particularly osteoporosis, compared with that achieved by the administration of the N-hydroxybenzamidine derivative or a salt thereof or the active vitamin D or a prodrug thereof alone.

The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.